← Back to Search

Antifibrotic Agent

interferon alpha 2b (Intron A) for Hypertrophic Scar

Phase 3
Waitlist Available
Led By Edward E Tredget, MD MSc FRCSC
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up once / month for 6 months
Awards & highlights

Summary

This study assesses the intervention with antifibrotic agents, specifically interferon (IFN) to reduce the magnitude and duration of hypertrophic scar. Burn patients with hypertrophic scar are randomly assigned to either an intervention IFN group or a placebo control group by subcutaneous injection three times a week. Patients are assessed using cutometer, mexameter, standardized photography, urinalysis, blood work, tissue biopsies and the Vancouver Burn Scar Assessment (VBSA) which rates selected HTS based on color, vascularity, height, pliability, itchiness and pain sensitivity. Once on treatment patients are assessed monthly for the six month treatment period.

Eligible Conditions
  • Hypertrophic Scar
  • Burns

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~once / month for 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and once / month for 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Systemic effect of Intron A on hypertrophic scar

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: interferon alpha 2b (Intron A)Experimental Treatment1 Intervention
1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered subcutaneously once a day for 7 days, then three times a week for 23 weeks.

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
917 Previous Clinical Trials
430,427 Total Patients Enrolled
Edward E Tredget, MD MSc FRCSCPrincipal InvestigatorUniversity of Alberta
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top